Osivax

Osivax is a clinical stage biotechnology company in France that focuses on developing a pipeline of vaccines and immunotherapies. Founded 2017 in Lyon, Rhone-Alpes, France by Alexandre Levert and Florence Nicolas, Osivax has raised a total of €10.7M in funding over two rounds. Their latest funding was raised on July 10, 2019 from a Series A round. Osivax is funded by three investors, with Meusinvest (Noshaq) and Cédric Delorme as the most recent investors. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medical practitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively.